secwatch.observer — SEC 8-K summary
======================================

Issuer:     PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB)
CIK:        0001299130
Form:       8-K
Filed at:   2026-08-05T20:23:30+00:00
Accession:  0001299130-26-000117
Event type: earnings
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 2.05, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PacBio Q2 revenue $39M, net loss $44.7M; CEO Henry steps down, Van Oene appointed; restructuring cuts 8% workforce
--------------------------------------------------------------------------------

- Q2 revenue $39.0M (down 2% YoY); GAAP net loss $44.7M ($0.14 loss per share); non-GAAP net loss $41.9M.
- Revio placements 20, Vega placements 26; consumable revenue $20.1M; annualized Revio pull-through ~$202K.
- Full-year 2026 revenue guidance $155-165M; commenced SPRQ-Nx chemistry rollout at $345/genome.
- CEO Christian Henry steps down effective Aug 5; COO Mark Van Oene appointed President and CEO; Henry stays as advisor through Dec 2026.
- Restructuring plan cuts ~40 employees (8% workforce); expects $30-40M annualized OpEx reduction by end 2027; $2M pre-tax charges in Q3.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1299130/000129913026000117/0001299130-26-000117-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1299130/000129913026000117/pacb-20260730.htm
  HTML page:      https://secwatch.observer/filing/0001299130-26-000117

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer